DNA topoisomerase I was purified to near homogeneity from a clonal line of human lymphoblastic leukemia cells, RPMI 8402, that is resistant to camptothecin, a cytotoxic alkaloid from Camptotheca acuminata, and compared with that of the parent wild-type cells. As assayed by relaxation of the supercoiled plasmid DNA and by formation of enzymelinked DNA breaks, the purified enzyme from the resistant cells was shown to be >125-fold as resistant to camptothecin as the wild-type enzyme, comparable to a cellular resistance index of about 300. Therefore, the cellular resistance appears to be due to the resistance of the enzyme. The amount of the immunoreactive enzyme protein in whole extract appeared to be reduced to less than half that of the wild-type enzyme. These results establish that DNA topoisomerase I is the cellular target of camptothecin and that DNA topoisomerase I is essential for the survival of mammalian cells.
The DNA topoisomerases are enzymes that catalyze the concerted breakage and rejoining of the DNA backbone and thereby are presumed to participate in various genetic processes (1) (2) (3) (4) (5) . The type I topoisomerases transiently cut and reseal one DNA strand so that the linking number changes by steps of one. Genetic and functional studies of the enzymes have been largely limited to prokaryotes and the lower eukaryote yeast. Viable mutants ofEscherichia coli defective in the topA gene encoding topoisomerase I were isolated (6, 7), but these proved to have mutations in DNA gyrase genes that compensated for the mutation in topA (8) (9) (10) . This finding suggested an essential role for the enzyme in regulating the degree of supercoiling of DNA by counteracting the activity of the type II enzyme. In contrast, however, topoisomerase I-deficient mutants of yeast were isolated and shown to be viable, although they possessed the wild-type allele of topoisomerase II (11, 12) . The effect of the topoisomerase I mutation, however, was manifested by an additional mutation in topoisomerase II, implicating the complementary role of the latter (12) .
Topoisomerase I was previously found associated with transcriptionally active chromatin in mammalian cells (13, 14) . It also appears to be catalytically active on transcriptionally active genes in Drosophila polytene chromosomes (15) as well as on nucleolus-associated ribosomal genes (16) (17) (18) (19) . These experiments suggest a functional role for the enzyme in transcriptional events involving either RNA polymerase I or II.
The availability of mutants and specific inhibitors of this enzyme as was the case in prokaryotes might help dissect and establish the role of this enzyme in DNA metabolism. We previously reported that heparin is a potent inhibitor of a mammalian DNA topoisomerase I (20, 21) , but its broad specificity limits its usefulness for this purpose. Camptothecin (CPT) is a cytotoxic alkaloid isolated from Camptotheca acuminata (22, 23) , which has a strong antitumor activity against a wide range of experimental tumors. CPT inhibits RNA and DNA synthesis and causes rapid and reversible fragmentation of DNA in mammalian cells (22, 24, 25) . Clinical application of CPT and its derivatives has been hampered by associated effects of myelosuppression and gastrointestinal symptoms (26) . A hydrophilic derivative of CPT, called 7-ethyl-10-[4-(1-piperidyl)-1-piperidyl]carbonyloxy-CPT (CPT-11), has proved to be remarkably effective as an antitumor agent with reduced side effects (27 Purification and Assays of DNA Topoisomerases. DNA topoisomerase I was purified essentially as described (30) with some modifications (to be described elsewhere). Briefly, chromatin was purified from cells, washed with 50 mM phosphate buffer containing Nonidet P-40 and phenylmethylsulfonyl fluoride (PhMeSO2F), and extracted With 0.2 M phosphate buffer. The extract was applied onto a heparinSepharose column. The enzymatic activity was eluted stepwise from 0.5 M to 0.7 M NaCi in the elution buffer containing 10% glycerol. The active fraction was then fractionated with a phenyl-Sepharose column. The activity was eluted stepwise from 0.9 M to 0.5 M ammonium sulfate in the elution buffer. Enzymatic activity was assayed by relaxation of supercoiled plasmid ColEl fNA (20, 30 (32) , and unknotting of knotted bacteriophage P4 head DNA (33) . Time in culture, days
Immunoblotting of Topoisomerase I. The total amount of topoisomerase I in the extract was determined by an immunoblotting technique (34) . The extract was prepared as described by Tricoli et al. (31) . In brief, 2.5 x 107 cells were lysed by hypotonic buffer containing Triton X-100 and PhMeSO2F and extracted with buffer containing 1 M NaCl. DNA was precipitated by polyethylene glycol (PEG). The PEG supernatant was used for immunoblotting and total activities of topoisomerase I and II. Aliquots were electrophoresed on NaDodSO4/polyacrylamide gels as described (30) , and the proteins were transferred to nitrocellulose membranes and processed for immunoblotting by the peroxidase-coupled biotin-avidin system.
Peptide Mapping Analysis of Topoisomerase I. Peptide mapping analysis was carried out by digestion of the enzyme by S. aureus protease V8 as described (30 (Fig. 2) . The CPT sensitivity of each enzyme was then measured in the presence of CPT, CPT-11, or SN38, one of the metabolites of CPT-11 (Fig. 3) . The wild-type enzyme was inhibited by CPT at 1 MuM and by SN 38 at 13 AM, whereas CPT-K5 enzyme was not inhibited by either CPT or SN 38 at the highest concentrations employed-i.e., 125 and 254 MM, respectively. CPT-11 did not affect the activity of wild-type enzyme even at 750 MxM. We next examined the effect of CPT on the formation of the enzyme-linked DNA intermediate (Fig. 4) total amount of the enzyme protein in the extract from both strains was then measured by immunoblotting (Fig. 5) . The extract proteins were electrophoresed on a NaDodSO4/ polyacrylamide gel and transferred to a nitrocellulose membrane. The membrane was stained as described in Materials and Methods. The content of the enzyme protein in the mutant cells seems to be reduced to less than half of that of the wild-type cells, suggesting that the specific activities of the two enzymes are similar. Furthermore, as seen in Fig. 5 , it was repeatedly observed that the apparent molecular weight of the mutant enzyme on NaDodSO4/polyacrylamide gel seems to be a little (by -1000) less than that of the wild-type enzyme. Topoisomerase II activity was determined in the same extracts by ATP-dependent catenation reaction (Table 1 and Fig. 6 ). Almost the same activities were detected in both cell lines in the presence of ATP. This was confirmed by two different assays-i.e., decatenation of kinetoplast DNA and unknotting of knotted P4 phage DNA.
Peptide Mapping of Topoisomerase I from Wild-Type and CPT-K5 Cells. Purified enzyme proteins from both cell lines were partially digested with S. aureus V8 protease, electrophoresed on a NaDodSO4/polyacrylamide gel, and silver stained as described (30) (Fig. 7) . No detectable differences were observed between the peptide composition of these enzymes. DISCUSSION A mutant cell line resistant to CPT-11 was isolated from cultured human lymphoblastic leukemia cells, RPMI 8402. DNA topoisomerase I purified from the resistant mutant CPT-K5 showed at least 125-fold higher resistance to CPT than did the wild-type enzyme (see Figs. 3 and 4) , indicating that the cellular resistance to the drug is primarily, if not entirely, due to the resistance of a structurally altered topoisomerase I. The enzyme is altered so that CPT can no longer bind to the domain that is functional in the resealing of the broken ends of the DNA strands, since CPT is known to inhibit only the resealing step of the enzymatic activity.
Based on these findings and our present knowledge of the enzymatic mechanism for DNA topoisomerase I, a working model for the drug action on the wild-type and the mutant enzyme is shown schematically in Fig. 8 (35) (36) (37) . CPT induces a reversible breakage of DNA in vivo (24, 25) and in vitro (28) . CPT is also reported to inhibit DNA synthesis in L5178Y and HeLa cells (38) and to be more cytotoxic to the cells in S phase than in G1 or G2 phase (39, 40) . In vitro studies have demonstrated that topoisomerase I is required for the elongation step of adenovirus DNA replication (41) . CPT induces sister-chromatid exchanges in Chinese hamster cells, V79 (42) . These data together with our findings lead us to conclude that topoisomerase I is required for the survival and growth of cells, playing a central role in transcription and replication of DNA by its swivel-like enzymatic activity.
It has been shown in E. coli and in yeast that DNA topoisomerase I functions in concert with topoisomerase II in vivo. In E. coli topoisomerase I is essential under any conditions for the maintenance of the proper degree of superhelicity of the genomic DNA (43) . However, in yeast topoisomerase I is dispensable as long as topoisomerase II functions normally, suggesting that topoisomerase II can be recruited to complement a defect in topoisomerase I. In mammalian cells the topoisomerase II cannot complement the function of topoisomerase I, as shown in this paper. This difference between the roles of the two enzymes in lower and higher eukaryotes might be due to some difference in the chromatin organization. 
